Cloud-Clone touts GAL1 antibody for immune and cancer research

Cloud-Clone Corp. is promoting a validated GAL1 antibody as a multi-application research tool for studying galectin-1 in immunity and oncology. The company says the reagent works across blotting, imaging, tissue staining and flow cytometry workflows.

Why it matters: - Galectin-1, or GAL1, sits at the intersection of immune regulation and tumor biology. - Researchers studying the protein need reliable reagents to track where GAL1 is expressed and how it behaves in different disease settings. - Cloud-Clone is positioning its GAL1 antibody as a tool for pre-clinical work in immunology and oncology.

What happened: - Cloud-Clone Corp. announced a validated GAL1 antibody for research use. - The company said the reagent is designed for multiple laboratory workflows, including Western blot, immunohistochemistry, immunofluorescence and flow cytometry. - The announcement was issued from Houston on Sept. 16, 2026.

The details: - GAL1 is a β-galactoside-binding lectin and the earliest discovered member of the galectin family. - The protein has an approximate molecular weight of 14.5 kDa. - GAL1 binds complex cell-surface glycan chains carrying β-galactoside residues. - In normal physiology, GAL1 helps maintain immune homeostasis by inducing apoptosis in activated effector T-cells. - In tumor settings, GAL1 is described as supporting immune escape, T-cell apoptosis, regulatory T-cell expansion, dendritic cell reprogramming, macrophage polarization and angiogenesis. - Elevated GAL1 levels are linked with poor prognosis across multiple cancer types. - In non-small-cell lung cancer, high GAL1 plasma levels have been associated with shorter median progression-free survival after anti-PD-1 immunotherapy. - In liver cancer, GAL1 is described as a driver of progression from hepatitis and fibrosis toward malignant transformation. - Cloud-Clone said both polyclonal and monoclonal versions of the antibody can selectively recognize GAL1. - In Western blot, the antibody detected GAL1 in K562 cells and mouse heart, liver and kidney tissue at 1 µg/mL. - In immunohistochemistry, the antibody stained GAL1 in porcine uterine tissue at 10 µg/mL, while PBS negative controls showed no detectable signal. - In immunofluorescence, the antibody showed intracellular GAL1 signal in K562 cells at 20 µg/mL. - In flow cytometry, the antibody produced a fluorescence shift in MDA-MB-231 breast cancer cells versus an isotype control. - The company said a neutralizing anti-GAL1 antibody can inhibit GAL1-mediated T-cell apoptosis and alter adhesion-dependent interactions between tumor cells and the extracellular matrix. - The product referenced in the release is Product No. PAA321Hu01.

Between the lines: - The release blends basic biology with product marketing, using GAL1's role in immune suppression and tumor progression to frame the antibody as more than a detection reagent. - Multi-assay validation matters because researchers often want one antibody that can work across tissue, cell and quantitative platforms. - The therapeutic angle suggests Cloud-Clone is also aiming to support antibody-development and target-validation research around GAL1.

What's next: - Further study of GAL1-glycan interactions could expand the role of GAL1 antibodies in translational research. - The company expects the reagent to support pre-clinical work that may inform future GAL1-targeted cancer immunotherapy strategies. - Cloud-Clone directs readers to More information on its company site.